JCEM: Relationship between antihypertensive drugs and severe hyponatremia

Calcium channel blockers (CCBs), receptor blockers (BBs), angiotensin conversion enzyme inhibitors (ACEIs) and angiotensin II blockers (ARBs) are occasionally reported to cause severe hyponatremiaRecently, the authoritative journal Journal of Endocrinology and Metabolic Diseases published a study in the journal Of Clinical Endocrinology and Metabolism to explore the relationship between CCBs, BBs, ACEIs, ARBs and hospitalization for hyponatremiaresearchers compared inpatients (14,359 cases) with the main diagnosis of hyponatremia with the control group (57,383) and linked to the National Population Registry for dataThe researchers used the regression of multivariate Logitic to explore the relationship between hospitalization for severe hyponatremia and the use of different CCBs, BBs, ACEIs, and ARBs, and adjusted for combination medications, diseases, past hospitalizations, and socioeconomic factorsIn addition, new users (for 90 days) and those taking the drug were evaluated separatelythe adjusted ratio of the four drugs analysed in the study (aORs) (95% CI) ranged from 0.93 (0.88-0.98) of BBs to 1.16 (1.09-1.24) of ARBsFor new drug users, the range of ORs fluctuates from 1.55 (1.35-1.78) of BBs to 3.82 (3.36-4.34) of CCBsIn contrast, the association with patients who continued to take the drug did not increase, ranging from 0.82 (0.77-0.87) to 1.07 (1.00-1.14)In the CCBs subgroup, the aOR for new vascular CCBs was 4.02 (3.53-4.58), while the aOR for continuous treatment was 0.84 (0.78-0.89), it is clear that new CCBs are associated with a significant increase in the risk of hospitalization for hyponatremiaFor new bBs, ACEIs and ARBs, the risk is moderately elevatedOn the contrary, there is no evidence that ongoing antihypertensive drug therapy increases the risk of hospitalization for hyponatremia